X4 Pharmaceuticals
About X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is developing two unique programs such as drug candidate, X4P-001, has clinical experience in over 70 subjects, and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC), the second program, X4P-002, is a unique series of late lead molecules that penetrate the blood-brain barrier. They will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program.
Company Metrics
- Employees: 51-100
- Monthly Visits: 6200
- Tech Stack: 18 active products
Financial Information
- Estimated Revenue: Less than $1M
- Total Funding: 239499999 USD
- Last Funding: 65000000 USD (Post-IPO Equity)
- Funding Status: IPO
Technology Stack
X4 Pharmaceuticals actively uses 18 products in their tech stack.
Market Presence
Industries: Biotechnology, Clinical Trials, Health Care, Pharmaceutical, Therapeutics
Headquarters: Cambridge, Massachusetts, United States
Leadership
Employees
- Adam Mostafa - Chief Financial Officer (LinkedIn)
- Art Taveras - Chief Scientific Officer (LinkedIn)
- Mark Baldry - Chief Commercial Officer (CCO) (LinkedIn)
- Mary Dibiase - Chief Operating Officer (LinkedIn)